Premium
Olmesartan‐associated duodenal villous atrophy, an emerging clinical issue
Author(s) -
Shukla Nupur,
Moore Kylies,
Gabb Genevieve M.
Publication year - 2020
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.14834
Subject(s) - olmesartan , medicine , villous atrophy , atrophy , gastroenterology , disease , blood pressure , coeliac disease
Duodenal villous atrophy with olmesartan was described in 2012, 10 years following registration of olmesartan. Clinical features are severe watery diarrhoea, usually occurring in association with weight loss. Onset is delayed, with a mean duration of prior exposure to olmesartan of 3 years. Diagnosis may be delayed. Symptoms resolve over weeks following cessation of olmesartan. Epidemiological studies suggest increased risk with olmesartan, rather than a class effect of all angiotensin receptor blockers. Post‐marketing surveillance for drug safety remains important.